Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 


 

Defensive Equity Portfolio, Series 54
Ticker Symbol: FENEQX

30 Holdings (As of Day of Deposit)
Ticker Company Name Initial
Weight
Price*
Consumer Staples (49.92%)
MO Altria Group, Inc. 3.33% $43.60
ADM Archer-Daniels-Midland Company 3.34% 44.39
KO The Coca-Cola Company 3.33% 47.93
STZ Constellation Brands, Inc. 3.36% 172.87
COST Costco Wholesale Corporation 3.33% 332.43
HSY The Hershey Company 3.30% 142.51
KMB Kimberly-Clark Corporation 3.32% 155.79
KR The Kroger Co. 3.33% 34.26
MDLZ Mondelez International, Inc. 3.32% 55.20
MNST Monster Beverage Corporation 3.33% 80.60
NSRGY Nestle S.A. 3.30% 117.17
PEP PepsiCo, Inc. 3.30% 135.12
PG The Procter & Gamble Company 3.34% 133.23
UL Unilever Plc 3.35% 58.78
WMT Walmart, Inc. 3.34% 130.20
Health Care (50.08%)
ABT Abbott Laboratories 3.35% 99.06
ABBV AbbVie Inc. 3.31% 92.67
AMGN Amgen Inc. 3.38% 234.65
BMY Bristol-Myers Squibb Company 3.32% 63.13
CNC Centene Corporation 3.35% 62.88
CI Cigna Corporation 3.31% 182.38
CVS CVS Health Corporation 3.35% 65.26
DHR Danaher Corporation 3.38% 200.01
JNJ Johnson & Johnson 3.31% 146.97
MRK Merck & Co., Inc. 3.34% 80.91
NVO Novo Nordisk A/S 3.35% 65.19
REGN Regeneron Pharmaceuticals, Inc. 3.38% 598.86
TMO Thermo Fisher Scientific Inc. 3.31% 407.24
UNH UnitedHealth Group Incorporated 3.36% 315.55
VRTX Vertex Pharmaceuticals Incorporated 3.28% 261.86

* As of the close of business on 8/11/20.
Market values are for reference only and are not indicative of your individual cost basis.


Not FDIC Insured • Not Bank Guaranteed • May Lose Value


Portfolio Summary
Initial Date of Deposit 8/12/2020
Initial Public Offering Price $10.00 per Unit
Portfolio Ending Date 8/12/2022
Historical 12-Month Distribution Rate of Trust Holdings* 1.71%
Historical 12-Month Distribution Per Unit* $0.1709
Cash CUSIP 30314Y301
Reinvestment CUSIP 30314Y319
Fee Accounts Cash CUSIP 30314Y327
Fee Accounts Reinvestment CUSIP 30314Y335

*There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The historical 12-month distribution per unit and historical 12-month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust’s distribution or distribution rate. Due to the negative economic impact across many industries caused by the recent COVID-19 outbreak, certain issuers of the securities included in the trust may elect to reduce the amount of dividends and/or distributions paid in the future. As a result, the “Historical 12-Month Distribution Rate of Trust Holdings,” which is based on the trailing twelve-month distributions paid by the securities included in a trust, will likely be higher, and in some cases significantly higher, than the actual distribution rate achieved by the trust. The historical 12-month distribution per unit is based on the weighted average of the trailing 12-month distributions paid by the securities included in the portfolio. The historical 12-month distribution rate is calculated by dividing the historical 12-month distributions by the trust’s offering price. The historical 12-month distribution and rate are reduced to account for the effects of fees and expenses, which will be incurred when investing in a trust. Certain of the issuers may have reduced their dividends or distributions over the prior 12 months. The distribution per unit and rate paid by the trust may be higher or lower than the amount shown above due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, or the sale of securities in the portfolio.


Sales Charges (based on a $10 public offering price)
Standard Accounts
Transactional sales charges: Initial: 0.00%
  Deferred: 2.25%
Creation and Development Fee:   0.50%
Maximum Sales Charge:   2.75%
Fee/Wrap Accounts
Maximum Sales Charge:   0.50%

The deferred sales charge will be deducted in three monthly installments commencing 11/20/20.

When the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price exceeds $10.00 per unit, you will pay an initial sales charge.

The maximum sales charge for investors in fee accounts consists of the creation and development fee. Investors in fee accounts are not assessed any transactional sales charges. Standard accounts sales charges apply to units purchased as an ineligible asset.

The creation and development fee is a charge of $0.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the creation and development fee will exceed 0.50%.

In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

You should consider the portfolio's investment objective, risks, and charges and expenses carefully before investing. Contact your financial professional or call First Trust Portfolios L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the portfolio. Read it carefully before you invest.

Risk Considerations
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

You should be aware that the portfolio is concentrated in stocks in both the consumer staples and health care sectors which involves additional risks, including limited diversification. The companies engaged in the consumer staples industry are subject to global competition, changing government regulations and trade policies, currency fluctuations, and the financial and political risks inherent in producing products for foreign markets. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

An investment in a portfolio containing equity securities of foreign issuers is subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers.

Large capitalization companies may grow at a slower rate than the overall market.

As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

The recent outbreak of a respiratory disease designated as COVID-19 was first detected in China in December 2019. The global economic impact of the COVID-19 outbreak is impossible to predict but is expected to disrupt manufacturing, supply chains and sales in affected areas and negatively impact global economic growth prospects. The COVID-19 outbreak has also caused significant volatility and declines in global financial markets, which have caused losses for investors. The impact of the COVID-19 outbreak may be short term or may last for an extended period of time, and in either case could result in a substantial economic downturn or recession.

The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

 
Fund Cusip Information
30314Y301 (Cash)
30314Y319 (Reinvest)
30314Y327 (Cash-Fee)
30314Y335 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page
 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2020 All rights reserved.